91,671 Shares in Abbott Laboratories $ABT Bought by NBT Bank N.A.

NBT Bank N.A. acquired a new stake in Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 91,671 shares of the healthcare product maker’s stock, valued at approximately $9,060,000.

Other institutional investors have also added to or reduced their stakes in the company. Parkway Wealth Management Group LLC increased its holdings in shares of Abbott Laboratories by 3.2% in the 3rd quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock worth $317,000 after purchasing an additional 98 shares in the last quarter. St. Johns Investment Management Company LLC raised its stake in shares of Abbott Laboratories by 1.0% in the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock worth $895,000 after purchasing an additional 101 shares during the last quarter. AA Financial Advisors LLC lifted its holdings in shares of Abbott Laboratories by 1.7% during the third quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock valued at $611,000 after purchasing an additional 101 shares in the last quarter. Eagle Bay Advisors LLC lifted its holdings in shares of Abbott Laboratories by 1.2% during the third quarter. Eagle Bay Advisors LLC now owns 8,448 shares of the healthcare product maker’s stock valued at $835,000 after purchasing an additional 102 shares in the last quarter. Finally, Richards Merrill & Peterson Inc. boosted its position in shares of Abbott Laboratories by 1.1% during the third quarter. Richards Merrill & Peterson Inc. now owns 9,562 shares of the healthcare product maker’s stock valued at $945,000 after buying an additional 102 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on ABT. TD Cowen reduced their price objective on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a report on Thursday. Robert W. Baird upped their target price on shares of Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research note on Thursday. JPMorgan Chase & Co. lowered their target price on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Finally, Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

Abbott Laboratories Stock Up 2.1%

Abbott Laboratories stock opened at $102.64 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The stock has a fifty day moving average of $105.30 and a 200 day moving average of $98.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a market cap of $177.61 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 1.86 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. The business had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the firm posted $1.30 earnings per share. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted EPS of $1.42, in line with the main consensus estimate, and revenue of $13.01 billion, slightly above the $12.99 billion estimate. Reported sales rose 14.5% year over year, while comparable sales increased 7%. Abbott third-quarter results
• Positive Sentiment: Abbott reaffirmed its full-year adjusted EPS guidance, and analysts continue to see upside. Wells Fargo raised its price target to $119, while Robert W. Baird raised its target to $123. Citigroup, RBC, JPMorgan, TD Cowen and BTIG lowered targets but retained bullish ratings, including “buy,” “outperform” or “overweight.”
• Positive Sentiment: The company received European approval for its Cologuard Plus colorectal-cancer screening test, expanding the potential market for its diagnostics portfolio. Abbott Cologuard Plus European approval
• Neutral Sentiment: Abbott plans a tax-free separation of its approximately $8.5 billion Nutrition business into an independent, publicly traded company by the end of 2027. Management says the move could give both businesses more focused investment strategies, but investors face execution, allocation and valuation uncertainty during the transition. Abbott Nutrition separation announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth outlook, citing pressure from diabetes-related pricing and weakness in parts of its electrophysiology and medical-device businesses. This softer outlook overshadowed the quarterly revenue performance and led several analysts to trim price targets. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator issued a notice involving infant-formula claims related to Nestlé India and Abbott, creating a limited regulatory overhang for Abbott’s Nutrition operations. India infant-formula regulatory notice

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.